AT-7519 hydrochloride
CAS No. 902135-91-5
AT-7519 hydrochloride ( AT 7519 Hydrochloride;AT7519 Hydrochloride )
Catalog No. M16486 CAS No. 902135-91-5
A potent CDK2 inhibitor with IC50 of 47 nM; also inhibits CDK1/4/5 with IC50 of 190/67/18 nM and shows selectivity over some kinases (Aurora A, IR kinase, MEK, PDK1, c-Abl, IC50>10 uM).
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
Size | Price / USD | Stock | Quantity |
5MG | 47 | In Stock |
|
10MG | 71 | In Stock |
|
25MG | 102 | In Stock |
|
50MG | 152 | In Stock |
|
100MG | Get Quote | In Stock |
|
200MG | Get Quote | In Stock |
|
500MG | Get Quote | In Stock |
|
1G | Get Quote | In Stock |
|
Biological Information
-
Product NameAT-7519 hydrochloride
-
NoteResearch use only, not for human use.
-
Brief DescriptionA potent CDK2 inhibitor with IC50 of 47 nM; also inhibits CDK1/4/5 with IC50 of 190/67/18 nM and shows selectivity over some kinases (Aurora A, IR kinase, MEK, PDK1, c-Abl, IC50>10 uM).
-
DescriptionA potent CDK2 inhibitor with IC50 of 47 nM; also inhibits CDK1/4/5 with IC50 of 190/67/18 nM and shows selectivity over some kinases (Aurora A, IR kinase, MEK, PDK1, c-Abl, IC50>10 uM); has antiproliferative activity against HCT116 cells with IC50 of 82 nM; exhibits good profile against cytochrome P450 isoforms (<30% inhibition at 10 uM for 1A2, 2D6, 3A4, 2C9, 2C19).Blood Cancer Phase 2 Clinical
-
SynonymsAT 7519 Hydrochloride;AT7519 Hydrochloride
-
PathwayAngiogenesis
-
TargetCDK
-
RecptorCDK2/CyclinA;CDK4/CyclinD1;CDK5/p35;CDK9/CyclinT;GSK-3β
-
Research AreaCancer
-
IndicationBlood cancer
Chemical Information
-
CAS Number902135-91-5
-
Formula Weight418.71
-
Molecular FormulaC16H18Cl3N5O2
-
Purity>98% (HPLC)
-
Solubility10 mM in DMSO
-
SMILESCl.CC1=C(C(=O)NC2=C(NN=C2)C(=O)NC2CCNCC2)C(Cl)=CC=C1
-
Chemical Name1H-Pyrazole-3-carboxamide, 4-[(2,6-dichlorobenzoyl)amino]-N-4-piperidinyl-, hydrochloride (1:1)
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Wyatt PG, et al. J Med Chem. 2008 Aug 28;51(16):4986-99.
2. Squires MS, et al. Mol Cancer Ther. 2009 Feb;8(2):324-32.
3. Dolman ME, et al. Clin Cancer Res. 2015 Nov 15;21(22):5100-9.
2. Squires MS, et al. Mol Cancer Ther. 2009 Feb;8(2):324-32.
3. Dolman ME, et al. Clin Cancer Res. 2015 Nov 15;21(22):5100-9.
molnova catalog
related products
-
THZ-1
A potent, selective, covalent CDK7 inhibitor with IC50 of 3.2 nM; also weakly inhibits CDK12 with IC50 of 250 nM; displays broad-based activity a subset of cancer cell lines with IC50s of <200 nM.
-
ON-013100
ON-013100 is an antineoplastic drug. ON-013100 also acts as a mitotic inhibitor that could inhibit Cyclin D1 expression.
-
Alsteropaullone
Alsteropaullone (9-Nitropaullone, NSC 705701) is a derivative of kenpaullone, ATP-competitive inhibitor of CDKs and GSK3β, inhibits Cdk1/cyclin B, Cdk2/cyclin A, Cdk2/cyclin E and Cdk5/p25 with IC50 of 35, 15, 200 and 40 nM.